Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Biomolecules for Nanodelivery
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biomolecules for Nanodelivery

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 9285

Special Issue Editors

Prof. Dr. Sang-Kyung Lee

E-Mail Website
Guest Editor
Department of Bioengineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, Korea
Interests: drug delivery; intranasal delivery; nanodelivery
Dr. Irfan Ullah

E-Mail
Guest Editor
Yale School of Medicinedisabled, Yale University, New Haven, CT 06510, USA
Interests: drug delivery; intranasal delivery; nanodelivery
Dr. Qurrat Ul Ain

E-Mail
Co-Guest Editor
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver Campus, 2405 Wesbrook Mall, Vancouver, BC, Canada
Interests: drug delivery; intranasal delivery; nanodelivery

Special Issue Information

Dear Colleagues,

Nanomedicine is the medical application of the knowledge and tools of nanotechnology to treat and prevent variety of emerging or exsisting diseases. It involves the use of wide-ranging nanoscale materials, such as biocompatible nanoparticles and nanorobots for diagnosis, delivery, sensing or actuation purposes in a living organism; there are even possible future applications of molecular nanotechnology in biological machines.

IJMS is a journal that provides a medium for the quality publication of full-length articles and review articles on all aspects of molecular sciences. For this Special Issue, manuscripts will be accepted ranging from molecular or genetic biologicals to biochemical, chemical or bioengineering concepts. However, in each case, the materials/biomaterials are directly relevant to biotechnological therapeutic systems. Papers presenting the multidisciplinary application of nanomedicine, which would not be suitable for publication in a journal devoted to a single discipline, are particularly welcome. The original research and  review articles describing the application of nanomedicine for cancer, neurological diseases and infectious diseases are strongly encouraged.

The following areas will be the main focus of this Special Issue:

  • Nucleic Acids/Molecular Biology
  • Nanomedicine
  • Biochemical Engineering/Bioengineering
  • Medicinal Biotechnology

Prof. Dr. Sang-Kyung Lee
Dr. Irfan Ullah
Guest Editors
Dr. Qurrat Ul Ain
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • gene therapy
  • DNA/RNA vaccine
  • gene editing
  • CRISPRi
  • biopolymers
  • nanoparticles
  • lipid nanoparticles
  • viral vectors
  • targeted deivery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2257 KiB  
Article
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
by Kateřina Jáklová, Tereza Feglarová, Simona Rex, Zbyněk Heger, Tomáš Eckschlager, Jan Hraběta, Petr Hodek, Matúš Kolárik and Radek Indra
Int. J. Mol. Sci. 2021, 22(8), 4250; https://doi.org/10.3390/ijms22084250 - 20 Apr 2021
Cited by 5 | Viewed by 2036
Abstract
A tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. Van is primarily used for the treatment of advanced or metastatic medullary thyroid cancer; however, its usage is significantly limited by side effects, particularly [...] Read more.
A tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. Van is primarily used for the treatment of advanced or metastatic medullary thyroid cancer; however, its usage is significantly limited by side effects, particularly cardiotoxicity. One approach to minimize them is the encapsulation or binding of Van in- or onto a suitable carrier, allowing targeted delivery to tumor tissue. Herein, we constructed a nanocarrier based on apoferritin associated with Van (ApoVan). Based on the characteristics obtained by analyzing the average size, the surface ζ-potential and the polydispersive index, ApoVan nanoparticles exhibit long-term stability and maintain their morphology. Experiments have shown that ApoVan complex is relatively stable during storage. It was found that Van is gradually released from its ApoVan form into the neutral environment (pH 7.4) as well as into the acidic environment (pH 6.5). The effect of free Van and ApoVan on neuroblastoma and medullary thyroid carcinoma cell lines revealed that both forms were toxic in both used cell lines, and minimal differences between ApoVan and Van were observed. Thus, we assume that Van might not be encapsulated into the cavity of apoferritin, but instead only binds to its surface. Full article
(This article belongs to the Special Issue Biomolecules for Nanodelivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 6460 KiB  
Review
Bioadhesive Nanoparticles for Local Drug Delivery
by Liu Yu, Zewen Luo, Tian Chen, Yaqi Ouyang, Lingyun Xiao, Shu Liang, Zhangwen Peng, Yang Liu and Yang Deng
Int. J. Mol. Sci. 2022, 23(4), 2370; https://doi.org/10.3390/ijms23042370 - 21 Feb 2022
Cited by 22 | Viewed by 3725
Abstract
Local drug delivery is an effective strategy for achieving direct and instant therapeutic effects. Current clinical treatments have fallen short and are limited by traditional technologies. Bioadhesive nanoparticles (NPs), however, may be a promising carrier for optimized local drug delivery, offering prolonged drug [...] Read more.
Local drug delivery is an effective strategy for achieving direct and instant therapeutic effects. Current clinical treatments have fallen short and are limited by traditional technologies. Bioadhesive nanoparticles (NPs), however, may be a promising carrier for optimized local drug delivery, offering prolonged drug retention time and steadily maintained therapeutic concentrations. In addition, the possibility of clinical applications of this platform are abundant, as most polymers used for bioadhesion are both biodegradable and biocompatible. This review highlights the major advances in the investigations of polymer-based bioadhesive nanoparticles and their innumerable applications in local drug delivery. Full article
(This article belongs to the Special Issue Biomolecules for Nanodelivery)
►▼ Show Figures

Figure 1

21 pages, 2501 KiB  
Review
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?
by Gudrun C. Thurner, Johannes Haybaeck and Paul Debbage
Int. J. Mol. Sci. 2021, 22(16), 8932; https://doi.org/10.3390/ijms22168932 - 19 Aug 2021
Cited by 5 | Viewed by 2882
Abstract
Nanoparticles bearing specific targeting groups can, in principle, accumulate exclusively at lesion sites bearing target molecules, and release therapeutic agents there. However, practical application of targeted nanoparticles in the living organism presents challenges. In particular, intravasally applied nanoparticles encounter physical and physiological barriers [...] Read more.
Nanoparticles bearing specific targeting groups can, in principle, accumulate exclusively at lesion sites bearing target molecules, and release therapeutic agents there. However, practical application of targeted nanoparticles in the living organism presents challenges. In particular, intravasally applied nanoparticles encounter physical and physiological barriers located in blood vessel walls, blocking passage from the blood into tissue compartments. Whereas small molecules can pass out of the blood, nanoparticles are too large and need to utilize physiological carriers enabling passage across endothelial walls. The issues associated with crossing blood-tissue barriers have limited the usefulness of nanoparticles in clinical applications. However, nanoparticles do not encounter blood-tissue barriers if their targets are directly accessible from the blood. This review focuses on osteoporosis, a disabling and common disease for which therapeutic strategies are limited. The target sites for therapeutic agents in osteoporosis are located in bone resorption pits, and these are in immediate contact with the blood. There are specific targetable biomarkers within bone resorption pits. These present nanomedicine with the opportunity to treat a major disease by use of simple nanoparticles loaded with any of several available effective therapeutics that, at present, cannot be used due to their associated side effects. Full article
(This article belongs to the Special Issue Biomolecules for Nanodelivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop